TriangleNCT00622505 · OUTCOME
Time to Death
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- years
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 2 years
What was measured
Time to death was defined as the time from the date of enrollment to the date of death. Participants who dropped out or completed the study were considered censored observations. Time to death was assessed by Kaplan-Meier method.
Analysis population: ITT analysis set included all participants who were enrolled in this study.
Groups in this outcome
Zoledronic Acid Every 12 Weeks
Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \<50 nmol/mmol creatinine).
Zoledronic Acid Every 4 Weeks or 12 Weeks
Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \<50 nmol/mmol creatinine, respectively).
| Group | Source count |
|---|---|
| Zoledronic Acid Every 12 Weeks | 79 |
| Zoledronic Acid Every 4 Weeks or 12 Weeks | 42 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zoledronic Acid Every 12 Weeks | NA | Not reported | NA | NA | The median and 95% CI was not estimable because there were too few events (low incidence of observed deaths) to calculate the median and 95% CI. |
| Zoledronic Acid Every 4 Weeks or 12 Weeks | NA | Not reported | NA | NA | The median and 95% CI was not estimable because there were too few events (low incidence of observed deaths) to calculate the median and 95% CI. |
Complete source fields
- classes
- categories
- measurements
- comment
- The median and 95% CI was not estimable because there were too few events (low incidence of observed deaths) to calculate the median and 95% CI.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- The median and 95% CI was not estimable because there were too few events (low incidence of observed deaths) to calculate the median and 95% CI.
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 79
- group Id
- OG001
- value
- 42
- units
- Participants
- description
- Time to death was defined as the time from the date of enrollment to the date of death. Participants who dropped out or completed the study were considered censored observations. Time to death was assessed by Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \<50 nmol/mmol creatinine).
- id
- OG000
- title
- Zoledronic Acid Every 12 Weeks
- description
- Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \<50 nmol/mmol creatinine, respectively).
- id
- OG001
- title
- Zoledronic Acid Every 4 Weeks or 12 Weeks
- param Type
- MEDIAN
- population Description
- ITT analysis set included all participants who were enrolled in this study.
- reporting Status
- POSTED
- time Frame
- Up to 2 years
- title
- Time to Death
- type
- SECONDARY
- unit Of Measure
- years
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice